LivaNova Reports First Quarter 2020 Results

Go back to LivaNova Reports First Quarter 2020 Results

Livanova (LIVN) PT Lowered to $65 at Piper Sandler

April 29, 2020 3:39 PM EDT

Piper Sandler analyst Matt O'Brien lowered the price target on Livanova (NASDAQ: LIVN) to $65.00 (from $80.00) while maintaining an Overweight rating.

negative commentary and outlook but lots value trapped in the stock... More

LivaNova plc (LIVN) Misses Q1 EPS by 10c, Revenues Miss; Updated FY20 EPS Guidance Below Consensus

April 29, 2020 6:21 AM EDT

LivaNova plc (NASDAQ: LIVN) reported Q1 EPS of $0.33, $0.10 worse than the analyst estimate of $0.43. Revenue for the quarter came in at $242.4 million versus the consensus estimate of $244.1 million.

"As a healthcare company committed to improving the lives of patients around the world, LivaNova is closely monitoring the COVID-19 situation. Being true to our values, we prioritize patients and their well-being, and we are working tirelessly to... More